Vimarsana
Biggest News Aggregation in the World

Fda Guidance News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Guidance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Guidance Today - Breaking & Trending Today

Eye on Pharma: Eylea Biosimilar Suspension; New FDA Labeling Guidance; Alvotech Reinspection - Vimarsana News

Eye on Pharma: Eylea Biosimilar Suspension; New FDA Labeling Guidance; Alvotech Reinspection

Samsung Bioepis suspends development for its biosimilar referencing Eylea (aflibercept); the FDA updates its labeling recommendations for interchangeable biosimilars; Alvotech receives a Form 483 after the FDA reinspected its Iceland-based manufacturing facility.

FDA begins investigating recalled applesauce - Vimarsana News

FDA begins investigating recalled applesauce

The U.S. Food and Drug Administration is screening imports of cinnamon from multiple countries for toxic lead contamination, after growing reports of children who were sickened after eating pouches of

FDA Guidance On Continuous Manufacturing Of Drug Substances And Drug Products - Food and Drugs Law - Vimarsana News

FDA Guidance On Continuous Manufacturing Of Drug Substances And Drug Products - Food and Drugs Law

In March 2023, the FDA issued a final guidance, titled "Q13 Continuous Manufacturing of Drug Substances and Drug Products" that describes scientific and regulatory considerations for the development...

Source: mondaq.com
Podcast about the FDA's CDS Software Guidance - Vimarsana News

Podcast about the FDA's CDS Software Guidance

The FDA issued a final guidance document clarifying how the agency intends to regulate clinical decision support software. Epstein Becker Green attorneys analyze the FDA’s latest CDS guidance and discuss the challenges as the industry makes sense of and comply with guidance.

FDA Infant Formula Discretion Policy - Vimarsana News

FDA Infant Formula Discretion Policy

FDA announced enforcement discretion policy which would allow certain non-compliant infant formula to be marketed in the US,which will remain in effect until November 14, 2022.FDA taking additional steps to facilitate use of Infant Formula under enforcement discretion policy